Study identifier:D7960C00010
ClinicalTrials.gov identifier:NCT06576765
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single-Dose, Non-Randomised, Open-label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
Hepatic Impairment
Phase 1
Yes
AZD0780
All
32
Interventional
18 Years - 85 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Group 1 Subjects with Moderate Impairment will receive a single oral dose of AZD0780 under fasted conditions. | Drug: AZD0780 Dose 1 Other Name: AZD0780 Other Name: Dose 1 |
Experimental: Group 2 Healthy participants will receive a single oral dose of AZD0780 under fasted conditions. | Drug: AZD0780 Dose 1 Other Name: AZD0780 Other Name: Dose 1 |
Experimental: Group 3 (optional) Subjects with Mild Impairment will receive a single oral dose of AZD0780 under fasted conditions. | Drug: AZD0780 Dose 1 Other Name: AZD0780 Other Name: Dose 1 |